If you’re trying to move your discovery from the lab to the marketplace, you might need some tools to make that happen. Check out our list of development and translational support available to you.
The CTSI Service Center provides a range of services and resources to investigators performing translational research across UF. The CTSI Service Center’s programs, resources and core facilities and how they can assist you can be found at: https://www.ctsi.ufl.edu/research/
We’re in the process of developing content. Come back and find more resources as we update our website and our calendar.
We’re in the process of developing content. Come back for more information as we update our website. If you have specific needs, please email us a firstname.lastname@example.org.
BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, has entered into a strategic collaboration with the University of Florida to translate research in genetically driven disease and cancers towards clinical development and potential commercialization.
Potential funding opportunities include:
UF faculty working interested in proposing a project that aligns with BridgeBio’s areas of interest outlined below should email email@example.com. to obtain more information. UF Innovate will review all proposals before submission to BridgeBio.
BridgeBio’s areas of interest are:
BARDA DRIVe programs accelerate the development and availability of transformative technologies and approaches to protect Americans from health security threats. Through public-private partnerships, DRIVe stimulates innovation though non-dilutive and dilutive funding and the DRIVe Accelerator Network connects BARDA to thirteen accelerators across the U.S. in regions where there is heavy activity in developing health security products and technologies in biotechnology, life science research, and medical innovations. The network supports early-stage companies throughout their journey – from identifying a need to product launch – to help them overcome their biggest business, marketing, and operational hurdles, and achieve success sooner. For more information about the various BARDA DRIVe programs visit this website.
The RADx Tech initiative aims to speed the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improve clinical laboratory tests, that can directly detect the COVID-19 virus. Visit the NIH RADx website to learn more about their various programs.
To learn more visit here. You may view slides from a June 2021 PFI Q&A Office Hours webinar as well as a recording of this webinar for more information about the program.
PFI-TT up to $250,000 for 18 months
The Technology Translation (PFI-TT) track offers an NSF-funded researcher the opportunity to advance her or his prior NSF-funded research results toward developing technological innovations with promising commercial potential and societal impact.
PFI-TT supports commercial potential demonstration projects for academic research outputs in any NSF-funded science and engineering discipline. This demonstration is achieved through proof-of-concept, prototyping, technology development and/or scale-up work.
Concurrently, students and postdoctoral fellows who participate in PFI-TT projects receive education and leadership training in innovation and entrepreneurship. Successful PFI-TT projects generate technology-driven commercialization outcomes that address societal needs.
The Research Partnerships (PFI-RP) track seeks to achieve the same goals as the PFI-TT track by supporting instead complex, multi-faceted technology development projects that are typically beyond the scope of a single researcher or institution and require a multi-organizational, interdisciplinary, synergistic collaboration.
A PFI-RP project requires the creation of partnerships between academic researchers and third-party organizations such as industry, non-academic research organizations, federal laboratories, public or non-profit technology transfer organizations or other universities.
Such partnerships are needed to conduct applied research on a stand-alone larger project toward commercialization and societal impact. In the absence of such synergistic partnership, the project’s likelihood for success would be minimal.
To receive guidance on IND, IDE application and reporting requirements contact:
Sheila Austin at the CTSI: firstname.lastname@example.org.
To receive guidance on regulatory submissions, informed consent, IRB submissions and clinical trials.gov registration and compliance contact Tiffany Danielle Pineda at the CTSI: email@example.com.